Omalizumab therapy could soon replace other, more toxic treatments
An international team of researchers has found that a once-a-month, high-dose injection of a commonly used asthma drug is highly effective in treating teens and adults chronically afflicted with hives and severe, itchy rash. The drug, omalizumab, was tested on 323 people at 55 medical centers for whom standard antihistamine therapy failed to quell their underlying, allergy-like reaction, known as chronic idiopathic urticaria or chronic spontaneous urticaria.
“Physicians and patients may now have a fast, safe and well-tolerated treatment option to consider before prescribing even more antihistamines, which can be highly sedating,” says Sarbjit (Romi) Saini, M.D., a Johns Hopkins allergist and immunologist, and study co-investigator. The research team’s findings are scheduled to be published in The New England Journal of Medicine online Feb. 24, to coincide with their initial presentation at the annual meeting of the American Academy of Allergy, Asthma & Immunology in San Antonio, Texas.
Participants in the study, which ran from 2009 to 2011, were mostly women and between the ages of 12 and 75. Each was randomly assigned to take one of three dosing regimens of omalizumab, or placebo, after which they were monitored through regular checkups for four months. Neither researchers nor participants were aware of what specific dose was being taken by which subjects during the study.
All study participants had chronic hives and rash for at least six months, with many having suffered from the condition for more than five years. All had continued to experience hives or a severe itchy rash for a full week while taking antihistamines.
“Patients suffering with this condition need more and better treatment options because chronic hives and rash are profoundly hard to treat and can be very debilitating,” says Saini, an associate professor at the Johns Hopkins University School of Medicine. Saini, who has studied omalizumab since 2005, points out that fewer than half of those treated respond to traditional drug treatments with antihistamines.
Saini says the new study results offer substantial evidence that this first injection treatment option not only works, but does so more safely than other drugs, such as corticosteroids and the immunosuppressant cyclosporine, which carry risk of potentially severe and toxic side effects, including high blood pressure, bone thinning and even infection. By contrast, headache was the most severe side effect observed with omalizumab therapy. No study participants died or suffered anaphylactic shock, or had to withdraw because of any adverse effects or events.
According to Saini, chronic idiopathic urticaria affects some 3 million Americans, and may or may not involve swelling, with twice as many women as men suffering from these often socially isolating conditions. Saini says some patients experience such severe swelling of their eyes, hands, face, lips and throat that they have difficulty breathing. Some refuse to leave home, losing several days at a time away from work during flare-ups.
In the study, the team of American and European researchers injected a 300-milligram dose of the drug, sold under the brand name Xolair, once a month for three months. Saini says initial relief from symptoms was quick and occurred after a week. After three months, 53 percent of people experienced a total elimination of all hives and 44 percent had no further incidents of hives or itch. Lower doses of the drug, at 150 milligrams and 75 milligrams, and the placebo (or 0 milligrams) proved half as effective as the next larger dose, or had almost no effect at all, researchers say.
The Latest Bing News on:
Treating chronic severe hives and itch
- CSU Can Affect All Aspects of Patients’ Lives, Explained Dr Jonathan Bernsteinon May 17, 2024 at 12:53 pm
The chronic nature of the hives affecting patients with chronic spontaneous urticaria (CSU) can really affect all aspects of their lives, including sleep, daily activities, work, and interpersonal ...
- What to do about rashes on skinon May 17, 2024 at 8:52 am
Rashes on the body can be both uncomfortable and concerning, affecting people of all ages and backgrounds. These skin irritations may range from mild ...
- Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularison May 15, 2024 at 7:01 am
In November 2023, Celldex presented first in class data from the Company’s Phase 1b study in PN demonstrating that barzolvolimab and its novel mast cell depleting mechanism could play a meaningful ...
- Patients With AD Prioritize Itch Control in Treatment Preferenceson May 14, 2024 at 3:41 pm
A US-based discrete choice experiment survey found that patients with atopic dermatitis (AD) prioritize treatments that effectively control itching.
- Treatments for endometrial cancer and chronic kidney disease associated itching added to Pharmaceutical Benefits Schemeon May 13, 2024 at 5:00 am
Difelikefalin (Korsuva) is used as a treatment for Australians with chronic kidney disease who are undergoing haemodialysis and have moderate to severe itching. Patients who suffer from the ...
- Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)on May 12, 2024 at 11:59 pm
If approved, Dupixent would be the first treatment in the U.S. indicated for adolescents aged 12-17 years with inadequately controlled CRSwNP, a ...
- Managing Comorbidities in Chronic Urticariaon May 9, 2024 at 7:51 am
"Patients with chronic urticaria should be recognized as a multimorbid group," noted the authors of a recent review in Frontiers in Allergy. "Management should involve recognizing and treating any ...
- For Your Patients: What's the Best Treatment for Hives?on May 8, 2024 at 9:00 pm
There are many different types of hives ... be increased when itch and other allergic symptoms are more severe. Your doctor may also decide to add an H2 antihistamine such as famotidine (Pepcid) or ...
- See The 50 Most Prescribed Drugs In The US Todayon May 8, 2024 at 11:29 am
Millions rely on medication to manage their health. Whether it’s a quick prescription to treat an illness or a long-term medication for a chronic illness, the vast majority of Americans do ...
- Man, 60, suffers multi-organ failure and narrowly escapes death after being stung by a beeon May 6, 2024 at 6:54 am
"The patient responded positively to the treatment and ... The reaction can cause itchy eyes, coughing, hives and vomiting. Anaphylaxis is associated with: Severe breathing difficulty due ...
The Latest Google Headlines on:
Treating chronic severe hives and itch
[google_news title=”” keyword=”treating chronic severe hives and itch” num_posts=”10″ blurb_length=”0″ show_thumb=”left”] [/vc_column_text]The Latest Bing News on:
Omalizumab
- Jasper Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Developmentson May 14, 2024 at 5:00 am
REDWOOD CITY, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit ...
- How to Treat Seasonal Allergieson May 12, 2024 at 1:00 pm
An injectable drug called Xolair (omalizumab) is designed to treat moderate to severe persistent allergic asthma. Lifestyle changes to minimize allergies In addition to medications, there are ...
- At 29, I discovered I have a life-threatening allergy – it’s ruined my lifeon May 9, 2024 at 10:02 pm
A new drug which limits allergic reaction to foods such as peanuts, eggs and dairy could change the lives of millions ...
- For Your Patients: What's the Best Treatment for Hives?on May 8, 2024 at 9:00 pm
Should symptoms persist, treatment with omalizumab (Xolair) is recommended. This biologic agent, which is administered by monthly injection, is the only treatment currently approved by the FDA for ...
- Buy Rating Affirmed for Celldex on Strong Barzolvolimab Trial Results and Positive Outlookon May 7, 2024 at 12:46 am
The drug met its primary endpoint in a Phase 2 study, showcasing a statistically significant mean change from baseline in the weekly urticaria activity score, which indicates a strong efficacy in ...
- Skin patch improves treatment for pediatric milk allergieson May 1, 2024 at 5:00 pm
In February, the FDA approved omalizumab, the first injectable medication for IgE-mediated food allergies in adults and children. However, there are currently no FDA-approved treatments ...
- Celltrion Submits BLA for Omalizumab Biosimilaron April 15, 2024 at 1:45 am
Last week, Celltrion USA announced it had submitted a BLA for CT-P39, a biosimilar to XOLAIR (omalizumab). Phase 3 studies demonstrated that in patients with chronic spontaneous urticaria ...
- Page settingson March 27, 2024 at 6:33 pm
Omalizumab is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma that is due to year-round allergens. Itching, bruising, redness, pain, or swelling at ...
- Asthma Drug Xolair Now Indicated For Food Allergies: Next Challenge Is Insurer Coverageon March 5, 2024 at 12:54 pm
Two weeks ago, the Food and Drug Administration approved Xolair (omalizumab) for immunoglobulin E-mediated food allergy in certain adults and children one year or older for the reduction of ...
- What Is a Sun Allergy?on July 30, 2023 at 10:04 am
Lindsay Curtis is a freelance health & medical writer in South Florida. Prior to becoming a freelancer, she worked as a communications professional for health nonprofits and the University of ...
The Latest Google Headlines on:
Omalizumab
[google_news title=”” keyword=”omalizumab” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]